The first wave of the GLP-1 era in the U.S. was defined by scarcity. Patients often waited for backlogged prescriptions, pharmacies rationed supply, and demand outpaced what manufacturers could deliver. That period is largely over. Tirzepatide and semaglutide are now regularly available, the range of clinical options has widened, and platforms such as Mochi Health […]